These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27684379)

  • 21. Response of asymptomatic cytomegalovirus viraemia to oral ganciclovir 3 g/day or 6 g/day in HIV-infected patients.
    Grzywacz M; Deayton JR; Bowen EF; Wilson P; Emery VC; Johnson MA; Griffiths PD
    J Med Virol; 1999 Nov; 59(3):323-8. PubMed ID: 10502264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Prophylaxis vs Pre-emptive Approach for Cytomegalovirus Infection in Kidney Transplant Recipients.
    Kır O; Zeytinoğlu A; Arda B; Yılmaz M; Aşçı G; Töz H
    Transplant Proc; 2017 Apr; 49(3):537-540. PubMed ID: 28340829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY; Wang Y; Han MZ; Huang H; Chen H; Liu QF; Wang JM; Liu T; Song YP; Ma J; Wu DP; Zou P; Huang XJ
    Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
    Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
    Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment.
    Allice T; Cerutti F; Pittaluga F; Varetto S; Franchello A; Salizzoni M; Ghisetti V
    J Virol Methods; 2008 Mar; 148(1-2):9-16. PubMed ID: 18045702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of CMV infection and disease in transplant patients. 27-29 February 2004.
    Razonable RR; Emery VC;
    Herpes; 2004 Dec; 11(3):77-86. PubMed ID: 15960905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.
    Chawla JS; Ghobadi A; Mosley J; Verkruyse L; Trinkaus K; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Uy GL; Westervelt P; DiPersio JF; Vij R
    Transpl Infect Dis; 2012 Jun; 14(3):259-67. PubMed ID: 22093134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy?
    Fehr T; Cippà PE; Mueller NJ
    Transpl Int; 2015 Dec; 28(12):1351-6. PubMed ID: 26138458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients.
    Gerna G; Furione M; Baldanti F; Percivalle E; Comoli P; Locatelli F
    Br J Haematol; 1995 Nov; 91(3):674-83. PubMed ID: 8555075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis.
    Beyar-Katz O; Bitterman R; Zuckerman T; Ofran Y; Yahav D; Paul M
    Clin Microbiol Infect; 2020 Feb; 26(2):189-198. PubMed ID: 31536817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
    Bueno J; Ramil C; Green M
    Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2013 May; 57(1):50-3. PubMed ID: 23403239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients.
    Kelly J; Hurley D; Raghu G
    J Heart Lung Transplant; 2000 Apr; 19(4):355-9. PubMed ID: 10775816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients.
    Rostaing L; Crespin A; Icart J; Lloveras JJ; Durand D; Martinet O; Didier J
    Transpl Int; 1994; 7 Suppl 1():S331-5. PubMed ID: 11271244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia.
    Sénéchal M; Dorent R; du Montcel ST; Fillet AM; Ghossoub JJ; Dubois M; Pavie A; Gandjbakhch I
    Clin Transplant; 2003 Oct; 17(5):423-7. PubMed ID: 14703924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia.
    Thompson G; Boan P; Baumwol J; Chakera A; MacQuillan G; Swaminathan S; Lavender M; Flexman J; James I; John M
    Pathology; 2018 Aug; 50(5):554-561. PubMed ID: 29945729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
    Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.